Clinical Trial Update: Intraocular Bevacizumab (Avastin) for Rubeosis Iridis [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating intravitreal bevacizumab (Avastin) for rubeosis iridis associated with glaucoma; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Rubeosis Iridis

Drugs mentioned

• Avastin (bevacizumab)

Snippet

Sponsor: Instituto de Olhos de Goiania | Conditions: Glaucoma, Rubeosis Iridis | Phase 4 | Status: COMPLETED